SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk

Neoplasia

Volumn 9, Issue 1, 2007, Pages 23-35

  Said, Neveen A ^a   Najwer, Ida ^a   Socha, Matthew J ^a   Fulton, David J ^a   Mok, Samuel C ^b   Motamed, Kouros ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

IL 6; LPA; Mesothelial cells; Ovarian cancer; SPARC

Indexed keywords

INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEONECTIN; PROTEIN KINASE B; STAT3 PROTEIN;

ARTICLE; ATTENUATION; CANCER CELL; CANCER INVASION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MESOTHELIUM; METASTASIS; MITOGENESIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 33846840798     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06658     Document Type: Article

References (38)

1. Hsia D, Lim S, Bernard-Trifilo J, Mitra S, Tanaka S, den Hertog J, Streblow D, Ilic D, Ginsberg M, and Schlaepfer D (2005). Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src. Mol Cell Biol 25, 9700-9712.
2. Schwartz B, Hong G, Morrison B, Wu W, Baudhuin L, Xiao Y, Mok S, and Xu Y (2001). Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 81, 291-300.
3. Guo R, Kasbohm E, Arora P, Sample C, Baban B, Sud N, Sivashanmugam P, Moniri N, and Daaka Y (2006). Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147, 4883-4892.
4. Bian D, Su S, Mahanivong C, Cheng R, Han Q, Pan Z, and Sun Pand Huang S (2004). Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 64, 4209-4217.
5. Li H, Ye X, Mahanivong C, Bian D, Chun J, and Huang S (2005). Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 280, 10564-10571.
6. Frankel A and Mills G (1996). Peptide and lipid growth factors decrease cis-diaminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res 2, 1307-1313.
7. j/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 26, 45-52.
8. Westermann A, Beijnen J, Moolenaar W, and Rodenhuis S (1997). Growth factors in human ovarian cancer. Cancer Treat Rev 23, 113-131.
9. Shen Z, Belinson J, Morton R, Xu Y, and Xu Y (1998). Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol 71, 364-368.
10. Ren J, Xiao Y, Singh L, Zhao X, Zhao Z, Feng L, Rose T, Prestwich G, and Xu Y (2006). Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66, 3006-3014.
11. Hodge D, Peng B, Cherry J, Hurt E, Fox S, Kelley J, Munroe D, and Farrar W (2005). Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65, 4673-4682.
12. Ogata A, Chauhan D, Teoh G, Treon S, Urashima M, Schlossman R, and Anderson K (1997). IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159, 2212-2221.
13. Yang L, Wang L, Lin H-K, Kan P-Y, Xie S, Tsai M-Y, Wang P-H, Chen Y-T, and Chang C (2003). Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 305, 462-469.
14. Syed V, Ulinski G, Mok S, and Ho SM (2002). Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 94, 617-629.
15. Sivashanmugam P, Tang L, and Daaka Y (2004). Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 279, 21154-21159.
16. Costanzo E, Lutgendorf S, Sood A, Anderson B, Sorosky J, and Lubaroff D (2005). Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104, 305-313.
17. Bradshaw A and Sage EH (2001). SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107, 1049-1054.
18. Said N and Motamed K (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167, 1739-1752.
19. Yiu G, Chan W, Ng S, Chan P, Cheung K, Berkowitz R, and Mok S (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159, 609-622.
20. Lu J, Xiao Yj Y, Baudhuin L, Hong G, and Xu Y (2002). Role of ether-linked lysophosphatidic acids in ovarian cancer cells. J Lipid Res 43, 463-476.
21. Sengupta S, Xiao Y, and Xu Y (2003). A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 17, 1570-1572.
22. Xu Y, Gaudette D, Boynton J, Frankel A, Fang X, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, et al. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1, 1223-1232.
23. Xu Y, Fang X, Casey G, and Mills G (1995). Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309 (Pt 3), 933-940.
24. Xu Y, Shen Z, Wiper D, Wu M, Morton R, Elson P, Kennedy A, Belinson J, Markman M, and Casey G (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280, 719-723.
25. Xu Y, Xiao Y, Baudhuin L, and Schwartz B (2001). The role and clinical applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Invest 8, 1-13.
26. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, et al. (2000). Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 905, 188-208.
27. Fang X, Yu S, Bast R, Liu S, Xu H, Hu S, LaPushin R, Claret F, Aggarwal B, Lu Y, et al. (2004). Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279, 9653-9661.
28. Mok S, Chan W, Wong K, Muto M, and Berkowitz R (1996). SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12, 1895-1901.
29. Plante M, Rubin S, Wong G, Federici M, Finstad C, and Gastl G (1994). Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73, 1882-1888.
30. van der Zee A, de Cuyper E, Limburg P, de Bruijn H, Hollema H, Bijzet J, Krans M, and de Vries E (1995). Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75, 1004-1009.
31. Offner F, Obrist P, Stadlmann S, Feichtinger H, Klingler P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B, et al. (1995). IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 7, 542-547.
32. Yao V, Platell C, and Hall J (2004). Peritoneal mesothelial cells produce inflammatory related cytokines. ANZ J Surg 74, 997-1002.
33. Obata N, Tamakoshi K, Shibata K, Kikkawa F, and Tomoda Y (1997). Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17, 337-342.
34. Nilsson M, Langley R, and Fidler I (2005). Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65, 10794-10800.
35. 2. Clin Cancer Res 6, 2482-2491.
36. Hu Y, Tee M, Goetzl E, Auersperg N, Mills G, Ferrara N, and Jaffe R (2001). Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93, 762-768.
37. Yun C, Sun H, Wang D, Rusovici R, Castleberry A, Hall R, and Shim H (2005). LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 289, C2-C11.
38. Kallen K-J (2002). The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta Mol Cell Res 1592, 323-343.